Abstract
Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day. Patients were males with a mean age of 63 years. Of the 86 patients, 71 (82%) had bronchitis caused by a single organism (29 by Haemophilus influenzae, 27 by Branhamella catarrhalis, 9 by gram-negative enteric organisms, 6 by Streptococcus pneumoniae), while more than one pathogen was implicated in 15 patients (18%). A total of 70.8% of the cefixime group and 50% of the cephalexin group were clinically cured (chi 2 = 3.89, P less than 0.05); however, when the categories of cured and improved were combined, no significant difference was noted between treatment groups (chi 2 = 3.39, P = 0.06). Analysis of side effects included all 130 evaluable and nonevaluable patients: diarrhea was noted in six patients in the cefixime group and none of the patients in the cephalexin group (P = 0.013 by the Fisher exact test). The diarrhea was mild and self-limited in all cases. B. catarrhalis has emerged as a major cause of exacerbation of bronchitis in our experience; there is an increased need to emphasize the examination of sputum samples by Gram staining if cos...Continue Reading
References
Mar 13, 1975·The New England Journal of Medicine·I Tager, F E Speizer
Feb 1, 1977·Antimicrobial Agents and Chemotherapy·M PfefferJ P de Menezes
Jan 1, 1989·Antimicrobial Agents and Chemotherapy·F A SarubbiS L Berk
Nov 1, 1989·Antimicrobial Agents and Chemotherapy·R J WallaceR E Weaver
Nov 1, 1987·Reviews of Infectious Diseases·H HagerS L Berk
Feb 1, 1988·Archives of Internal Medicine·C J SchleupnerB Vogelman
Oct 1, 1987·The Pediatric Infectious Disease Journal·F P TallyK Cartwright
Jan 1, 1986·Drugs·J A PollardR W Wilson
Feb 1, 1987·Annals of Internal Medicine·N R AnthonisenN A Nelson
Oct 1, 1987·The Pediatric Infectious Disease Journal·R D FaulknerB M Silber
Apr 1, 1985·Antimicrobial Agents and Chemotherapy·K G SweeneyC A Needham
Apr 1, 1985·Antimicrobial Agents and Chemotherapy·S AlvarezS L Berk
May 1, 1986·Archives of Internal Medicine·B NicotraR J Wallace
Apr 1, 1972·British Journal of Diseases of the Chest·A PinesM E Solari
Sep 1, 1969·JAMA : the Journal of the American Medical Association·M E LevisonD Kaye
Oct 16, 1965·British Medical Journal·P C ElmesT S Wilson
Jul 1, 1982·Annals of Internal Medicine·M B NicotraR J Awe
Nov 30, 1957·British Medical Journal·P C ELMESA A DUTTON
Citations
Jun 15, 2004·Vaccine·Diana G AdlowitzTimothy F Murphy
Apr 9, 1999·Vaccine·J M Kyd, A W Cripps
Oct 16, 1999·Vaccine·J KydT F Murphy
Jul 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·C Carbon
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Uwe WenzelHannelore Daniel
Apr 9, 2001·Clinical Microbiology Reviews·S Sethi, T F Murphy
Nov 15, 2006·Infection and Immunity·Pablo D BeckerSaúl Grinstein
Oct 18, 2000·Infection and Immunity·T F MurphyT J Hiltke
May 12, 2001·Infection and Immunity·T F MurphyC Kirkham
Oct 14, 2008·BMC Medicine·Milo A PuhanGerben Ter Riet
May 1, 1996·Clinical Therapeutics·R Quintiliani
Mar 20, 1998·Infection·W Ziering, P McElvaine
Jul 14, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F de Lalla
Feb 5, 2008·Journal of Immunological Methods·Taras ManolovKristian Riesbeck
Jun 13, 1998·Thorax·T F Murphy
Aug 24, 1999·Infection and Immunity·T F MurphyS Sethi
Mar 1, 1996·The Annals of Pharmacotherapy·B S SchatzG S Itokazu
Dec 1, 1994·Postgraduate Medicine·Abraham Verghese, Hassan M Ismail
Jun 1, 1996·Microbiological Reviews·T F Murphy